{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:01:57Z","timestamp":1793307717205,"version":"4.5.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T00:00:00Z","timestamp":1392940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0088865","type":"journal-article","created":{"date-parts":[[2014,2,21]],"date-time":"2014-02-21T16:59:50Z","timestamp":1393001990000},"page":"e88865","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1"],"prefix":"10.1371","volume":"9","author":[{"given":"Sharmila","family":"Mallya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana A.","family":"Fitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Scott","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lomon","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Janes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fruman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,2,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood-2009-09-220020","article-title":"Targeting the translational machinery as a novel treatment strategy for hematologic malignancies","volume":"115","author":"PR Hagner","year":"2010","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc2824","article-title":"Translational control in cancer","volume":"10","author":"D Silvera","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nm1042","article-title":"The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis","volume":"10","author":"D Ruggero","year":"2004","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.18632\/oncotarget.218","article-title":"Targeting translation dependence in cancer","volume":"2","author":"A Malina","year":"2011","journal-title":"Oncotarget"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR Signaling in Growth Control and Disease","volume":"149","author":"M Laplante","year":"2012","journal-title":"Cell"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bjc.6602902","article-title":"mTOR signaling: implications for cancer and anticancer therapy","volume":"94","author":"E Petroulakis","year":"2006","journal-title":"Brit J Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"S Wullschleger","year":"2006","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1158\/1078-0432.CCR-10-0480","article-title":"Target of rapamycin signaling in leukemia and lymphoma","volume":"16","author":"C Vu","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","article-title":"Regulation of translation initiation in eukaryotes: mechanisms and biological targets","volume":"136","author":"N Sonenberg","year":"2009","journal-title":"Cell"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"pe24","DOI":"10.1126\/scisignal.267pe24","article-title":"The pharmacology of mTOR inhibition","volume":"2","author":"DA Guertin","year":"2009","journal-title":"Sci Signal"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"AY Choo","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"D Benjamin","year":"2011","journal-title":"Nat Rev Drug Discovery"},{"key":"ref13","first-page":"241","article-title":"New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs)","volume":"347","author":"ME Feldman","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI44145","article-title":"Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy","volume":"121","author":"SA Wander","year":"2011","journal-title":"J Clin Invest"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.18632\/oncotarget.799","article-title":"mTOR inhibitor efficacy is determined by the eIF4E\/4E-BP ratio","volume":"3","author":"T Alain","year":"2012","journal-title":"Oncotarget"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Martineau Y, Azar R, Muller D, Lasfargues C, El Khawand S, <etal>et al<\/etal>.. (2013) Pancreatic tumours escape from translational control through 4E-BP1 loss. Oncogene 2013; PMID:23563181; <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dx.doi.org\/10.1038\/onc.2013.100\" xlink:type=\"simple\">http:\/\/dx.doi.org\/10.1038\/onc.2013.100<\/ext-link>.","DOI":"10.1038\/onc.2013.100"},{"key":"ref17","first-page":"302570","article-title":"Novel therapies for aggressive B-cell lymphoma","volume":"2012","author":"KA Foon","year":"2012","journal-title":"Adv Hematol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"MR Janes","year":"2010","journal-title":"Nat Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2012.276","article-title":"Efficacy of the investigational mTOR kinase inhibitor MLN0128\/INK128 in models of B-cell acute lymphoblastic leukemia","volume":"27","author":"MR Janes","year":"2013","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/leu.2010.154","article-title":"The dual PI3K\/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma","volume":"24","author":"PM Bhende","year":"2010","journal-title":"Leukemia"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2009-05-220889","article-title":"Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2","volume":"114","author":"M Gupta","year":"2009","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"BJ Lannutti","year":"2011","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1158\/1078-0432.CCR-11-2750","article-title":"Dual mTORC1\/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy","volume":"18","author":"C Garcia-Garcia","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","volume":"485","author":"AC Hsieh","year":"2012","journal-title":"Nature"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, <etal>et al<\/etal>.. (2013) Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2013. PMID:23542178 doi:10.1038\/onc.2013.92.","DOI":"10.1038\/onc.2013.92"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1084\/jem.20052204","article-title":"Inactivation of the PRDM1\/BLIMP1 gene in diffuse large B cell lymphoma","volume":"203","author":"L Pasqualucci","year":"2006","journal-title":"J Exp Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2004.05.024","article-title":"Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells","volume":"5","author":"S Avdulov","year":"2004","journal-title":"Cancer Cell"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"47419","DOI":"10.1074\/jbc.M405885200","article-title":"Structurally distinct elements mediate internal ribosome entry within the 5\u2032-noncoding region of a voltage-gated potassium channel mRNA","volume":"279","author":"GM Jang","year":"2004","journal-title":"J Biol Chem"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0088865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T17:34:46Z","timestamp":1565199286000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0088865"}},"subtitle":[],"editor":[{"given":"Robert W.","family":"Sobol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,21]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0088865","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,21]]}}}